期刊文献+

奈达铂联合替加氟治疗晚期食管癌近期疗效观察 被引量:3

下载PDF
导出
摘要 目的观察奈达铂联合替加氟治疗晚期食管癌的近期疗效。方法将56例患者分为A、B两组,A组(29例)给予NDP+CF+TF;B组(27例)给予NDP+CF+5-FU。每21天为1个周期,2个周期后评价疗效及毒副反应。结果A、B两组方案治疗CR+PR分别为75.9%(22/29)和48.1%(13/27),A组明显好于B组(P<0.05)。毒副反应主要是骨髓抑制,但两组之间差异无统计学意义;而静脉炎和黏膜炎发生率A组均低于B组(P<0.05)。结论奈达铂联合替加氟方案是治疗晚期食管癌安全、有效、易行的化疗方案。
出处 《实用肿瘤杂志》 CAS 北大核心 2009年第5期515-516,共2页 Journal of Practical Oncology
  • 相关文献

参考文献5

二级参考文献88

  • 1管忠震,徐瑞华.奈达铂临床研究进展[J].中国肿瘤临床,2004,31(13):774-780. 被引量:176
  • 2刘向明,钱碧云,屈大望,姜宏景,马明全.奈达铂联合氟尿嘧啶治疗中晚期食管癌的临床观察[J].临床肿瘤学杂志,2006,11(6):437-439. 被引量:22
  • 3白取治ほか.c野义制药研究所论文报告集[C].,1992.2123.
  • 4禾田透ほか.c野义制药研究所论文报告集[C].,1993.2375.
  • 5户谷刂兢郅.c野义制药研究所论文报告集[C].,1992.2241.
  • 6小原收ほか.c野义制药研究所论文报告集[C].,1993.2374.
  • 7[1]Devesa SS,Blot WJ,Fraumeni JF.Changing patterns in the incidence of esophageal and gastric carcinoma in the United States.Cancer,1998,83:2049
  • 8[2]Bollschweiler E,Wolfgarten E,Gutschow C,et al.Demographic variations in the rising incidence of esophageal adenocarcinoma in white males.Cancer,2001,92:549
  • 9[3]Ilson DH.Oesophageal cancer:New developments in systemic therapy.Cancer Treat Rev,2003,29 (6):525
  • 10[4]Anderson SE,Minsky RD,Bains M et al.Combined modality therapy in esophageal cancer:The Memorial experience.Semin Surg Oncol,2003,21:228

共引文献271

同被引文献44

  • 1管忠震,徐瑞华.奈达铂临床研究进展[J].中国肿瘤临床,2004,31(13):774-780. 被引量:176
  • 2赵海燕,张传建,牟建国.奈达铂联合放疗治疗中晚期食管癌的临床观察[J].临床肿瘤学杂志,2005,10(3):299-300. 被引量:8
  • 3李苏宜,孙新臣,刘琳.食管癌内科治疗及综合治疗进展[J].癌症,2006,25(4):509-515. 被引量:25
  • 4徐腾云,胡冰,庄建生.奈达铂联合5-氟脲嘧啶治疗晚期食管癌24例[J].中国肿瘤临床,2006,33(18):1038-1040. 被引量:5
  • 5邹小农.食管癌流行病学[J].中华肿瘤防治杂志,2006,13(18). 被引量:63
  • 6Meredith KL, Weber JM, Turaga KK, et al. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer [J]. Ann Surg Oncol, 2010,17(4) :1159 -1167.
  • 7Deng T, Zhang Y. 5-Aza-2'-deoxycytidine reactivates expression of RUNX3 by deletion of DNA methyltransferases leading to caspase independent apoptosis in colorectal cancer Lovo cells [ J ]. Biomed Pharmacother, 2009,63 (7) :492 - 500.
  • 8Raynal N J, Momparler LF, Rivard GE, et al. 3- Deazauridine enhances the antileukemic action of 5-aza- 2'-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase [ J ]. Leuk Res, 2011,35(1) :110 - 118.
  • 9Raynal NJ, Charbonneau M, Momparler LF, et al. Synergistic effect of 5-Aza-2'-deoxycytidine and genistein in combination against leukemia [J]. Oncol Res, 2008, 17(5) :223 -230.
  • 10Tang M, Xu W, Wang Q, et al. Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy [ J ]. Curr Genomics, 2009,10 (5) :336 - 352.

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部